title: Antibiotic bill doesn't GAIN enough ground.
abstract: With an eye to tackling the growing problem of antimicrobial drug resistance, uS lawmakers last month proposed new incentives to jump-start the ailing antibiotic industry. but the legislation as written is not likely to have the intended consequences, as it fails to adequately shield companies from competition with generic drugs. To truly entice investment and research from the drug industry, the bill needs to simplify the path to regulatory approval, provide greater protection from generic competition and aid drug companies with intellectual property extensions, tax relief and guaranteed market commitments.
authors: Institute for Clinical Pharmacodynamics in Latham, New York, USA.
authors: Paul G
authors: PG
authors: Ambrose
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D024881:Drug Resistance, Bacterial; D006801:Humans; D007880:Legislation, Drug; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
chemical_list: D000900:Anti-Bacterial Agents